8 / 38
0
10
20
30
40
50
60
70
80
90
100
%TumorStaining
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39
Cases
SP263
SP142
28-8
22C3
Blueprint phase 1
1
NCCN study
2
AstraZeneca study
4
French study
3
•
More than 90%
concordance between
22C3, 28-8 and SP263
assays for TC staining
• Similar interpretation
guidelines
•
SP142 : lower
sensitivity
to detect
PD-L1 expression in
tumor cells
1. Hirsch FR, et al.
J Thorac Oncol
. 2017 ;12(2):208-222. 2. Rimm D et al.
JAMA Oncol
. 2017 ;3(8):1051-1058 3. Adam J –
Ann Oncol 2018 4. Ratcliffe MJ et al.
Clin Cancer Res
. 2017;23(14):3585-3591.
Courtesy of Prof Besse
Comparison of PD-L1 assays in NSCLC